X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs ALEMBIC LTD - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD ALEMBIC LTD BIOCON LTD/
ALEMBIC LTD
 
P/E (TTM) x 96.0 52.3 183.6% View Chart
P/BV x 8.1 2.2 372.6% View Chart
Dividend Yield % 0.1 0.5 30.5%  

Financials

 BIOCON LTD   ALEMBIC LTD
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
ALEMBIC LTD
Mar-18
BIOCON LTD/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs1,18872 1,650.0%   
Low Rs30534 899.7%   
Sales per share (Unadj.) Rs68.74.7 1,462.0%  
Earnings per share (Unadj.) Rs7.66.1 123.7%  
Cash flow per share (Unadj.) Rs14.06.2 223.7%  
Dividends per share (Unadj.) Rs1.000.20 500.0%  
Dividend yield (eoy) %0.10.4 35.5%  
Book value per share (Unadj.) Rs86.340.7 212.4%  
Shares outstanding (eoy) m600.00267.03 224.7%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.911.3 96.4%   
Avg P/E ratio x98.98.7 1,139.5%  
P/CF ratio (eoy) x53.48.5 630.2%  
Price / Book Value ratio x8.61.3 663.9%  
Dividend payout %13.23.3 404.1%   
Avg Mkt Cap Rs m447,90014,139 3,167.8%   
No. of employees `0006.1NA-   
Total wages/salary Rs m9,311207 4,489.4%   
Avg. sales/employee Rs Th6,705.8NM-  
Avg. wages/employee Rs Th1,514.2NM-  
Avg. net profit/employee Rs Th736.9NM-  
INCOME DATA
Net Sales Rs m41,2341,255 3,285.1%  
Other income Rs m2,062370 557.0%   
Total revenues Rs m43,2961,625 2,663.7%   
Gross profit Rs m8,291111 7,462.6%  
Depreciation Rs m3,85138 10,187.8%   
Interest Rs m6152 36,176.5%   
Profit before tax Rs m5,887442 1,332.5%   
Minority Interest Rs m2130-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,56924 6,551.1%   
Profit after tax Rs m4,5311,630 278.0%  
Gross profit margin %20.18.9 227.2%  
Effective tax rate %26.75.4 491.6%   
Net profit margin %11.0129.8 8.5%  
BALANCE SHEET DATA
Current assets Rs m41,4861,867 2,221.9%   
Current liabilities Rs m21,413591 3,622.0%   
Net working cap to sales %48.7101.6 47.9%  
Current ratio x1.93.2 61.3%  
Inventory Days Days6494 67.9%  
Debtors Days Days9474 128.1%  
Net fixed assets Rs m50,6611,791 2,828.8%   
Share capital Rs m3,000534 561.7%   
"Free" reserves Rs m48,80810,324 472.8%   
Net worth Rs m51,80810,858 477.2%   
Long term debt Rs m17,89841 43,441.7%   
Total assets Rs m99,89711,591 861.9%  
Interest coverage x10.6260.9 4.1%   
Debt to equity ratio x0.30 9,104.3%  
Sales to assets ratio x0.40.1 381.1%   
Return on assets %5.214.1 36.6%  
Return on equity %8.715.0 58.3%  
Return on capital %9.615.2 63.4%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m12,05819 62,154.6%   
Fx outflow Rs m7,348264 2,785.2%   
Net fx Rs m4,710-244 -1,927.0%   
CASH FLOW
From Operations Rs m6,621236 2,807.9%  
From Investments Rs m-6,840-224 3,053.6%  
From Financial Activity Rs m-2,397-27 9,011.3%  
Net Cashflow Rs m-2,612-15 17,648.6%  

Share Holding

Indian Promoters % 40.4 64.0 63.1%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 0.2 4,200.0%  
FIIs % 10.7 9.7 110.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 26.1 76.2%  
Shareholders   109,995 54,701 201.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Positively, Aavas Financiers IPO, and Top Stocks in Action Today(Pre-Open)

Share markets in India ended on a positive note yesterday with gains largely seen in the banking sector and healthcare sector.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Sep 25, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS